@article{86f6ff6070884dd79942282efefe0c61,
title = "The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: A randomised, placebo-controlled trial",
abstract = "This was a nested sub-study of a randomised placebo-controlled trial of the effect of 6 months of treatment with rosiglitazone added to existing therapy on myocardial triglyceride (mTG) content in patients with type 2 diabetes (T2D) and prevalent cardiovascular disease (CVD) or at least one additional risk factor. The primary endpoint, mTG content, was measured with cardiac 1H-magnetic resonance spectroscopy. Of the 99 randomised participants selected for the imaging sub-study, 49 (48%) had complete and interpretable spectroscopy data (age = 58 years, duration of T2D = 9.5 years; 57% women and 69% non-white). There was no significant change in mTG in either group (?0.1 ± 0.6% and ?0.05 ± 0.8% respectively) and the changes in mTG were not associated with changes in left ventricular structure or function. Compared with placebo, treatment with rosiglitazone for 6 months had no discernible effect on mTG or left ventricular function in this population with long-standing diabetes and CVD.",
keywords = "Lipotoxicity, MRI, Steatosis, Thiazolidinedione",
author = "Jonathan McGavock and Szczepaniak, {Lidia S.} and Ayers, {Colby R.} and Abdullah, {Shuaib M} and Raphael See and {Odette Gore}, M. and Drazner, {Mark H} and {de Lemos}, {James A} and McGuire, {Darren K}",
note = "Funding Information: This work was supported by research grants from GlaxoSmithKline (GSK); Biosite, Inc.; the Donald W. Reynolds Foundation; and the United States Public Health Services General Clinical Research Center (grant #M01-RR00633) from National Institutes of Health/National Center Research Resources-Clinical Research. JMM was supported by a Target Obesity postdoctoral fellowship from the Canadian Institutes of Health Research, Canadian Diabetes Association and the Heart and Stroke Foundation of Canada. The funding organisations did not participate in study design, data collection, analysis or interpretation, writing of the report, or the decision to submit the paper for publication. Representatives of GSK reviewed the manuscript prior to submission, but did not contribute to its content. The corresponding author had full access to all of the data in the study, takes responsibility for the integrity of the data and the accuracy of the data analysis, and had final responsibility for the decision to submit for publication. Funding Information: DKM reports receiving honoraria from Pfizer and Takeda and consultancy fees from Novo Nordisk, Tethys Bioscience, and AstraZeneca. MHD reports receiving honoraria from GlaxoSmithKline. LSS reports receiving grant support from GlaxoSmithKline and Takeda. SMA, JMM, JAL, RS, MOG and CRA report no financial relationships.",
year = "2012",
month = apr,
doi = "10.1177/1479164111428628",
language = "English (US)",
volume = "9",
pages = "131--137",
journal = "Diabetes and Vascular Disease Research",
issn = "1479-1641",
publisher = "SAGE Publications Ltd",
number = "2",
}